Developer docs
API playgroundTry for free, no card

Search company profiles

Jaguar Gene Therapy

Full company profile

uuid0000dvz

Namestring
Jaguar Gene Therapy
Legal namestring
Jaguar Gene Therapy, LLC
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Jaguar Gene Therapy is a clinical-stage biotechnology company developing AAV9-based gene therapies for severe genetic diseases with significant unmet medical need. Founded in 2020 by former AveXis leadership and backed by Deerfield Management, the company is headquartered in Lake Forest, Illinois, with process sciences and manufacturing operations in Cary and Durham, North Carolina. Its core product candidates are JAG201, an AAV9 vector delivering a functional SHANK3 minigene via intracerebroventricular (ICV) injection for SHANK3 haploinsufficiency / Phelan-McDermid syndrome (lead clinical-stage program, currently in first-in-human dosing); JAG101, delivering the GALT gene for Type 1 galactosemia (preclinical); and JAG301, using PAX4-mediated transdifferentiation to convert alpha cells into beta cells for Type 1 diabetes (preclinical). A fourth program, AXV101 for BBS1-related Bardet-Biedl syndrome, is being developed by majority-owned subsidiary Axovia Therapeutics.

The company leverages a proven AAV9 delivery platform, exclusive licenses to foundational IP from the Broad Institute (JAG201) and Tulane University (JAG301), and vertically integrated CMC and manufacturing capabilities through a $125 million, 174,000-square-foot commercial facility in Durham, NC, owned by Alexandria Real Estate. JAG201 has received Rare Pediatric Disease, Fast Track, and Orphan Drug designations from the FDA, and Cohort 1 dosing was completed in February 2026 with no treatment-related serious adverse events reported.

Jaguar is pre-revenue and monetizes through eventual commercialization of one-time gene therapy treatments, supplemented by patient identification partnerships (e.g., CureSHANK, Phelan-McDermid Syndrome Foundation, Galactosemia Foundation, NORD) and a diagnostic collaboration with GeneDx. Its go-to-market is anchored in deep engagement with rare-disease patient communities and KOLs at leading academic centers such as Mount Sinai, Rush University, and Boston Children's Hospital, while investor syndicate includes Eli Lilly, Deerfield Management, ARCH Venture Partners, Goldman Sachs, Nolan Capital, Samsung Ventures, and the JDRF T1D Fund.

Short descriptiontext

Jaguar Gene Therapy is a clinical-stage, pre-revenue biotechnology company developing AAV9-based gene therapies — lead candidate JAG201 for SHANK3 haploinsufficiency/Phelan-McDermid syndrome (in first-in-human dosing), plus JAG101 (galactosemia) and JAG301 (Type 1 diabetes) — for patients with severe genetic diseases lacking approved treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLake Forest, United States
HQ citystring
Lake Forest
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, rare disease therapeutics, genetic disease treatment, gene replacement therapy, biologics manufacturing
Industry5 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy / Rare Disease Biologics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biotechnology company, Jaguar Gene Therapy is pre-revenue. The company is developing investigational gene therapies (JAG101, JAG201, JAG301) targeting severe genetic diseases. Revenue will be generated through commercialization of approved gene therapy products once clinical trials are completed and regulatory approvals are obtained.

jaguargenetherapy.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Jaguar Gene Therapy develops investigational AAV9-based gene therapies targeting the root causes of severe genetic diseases with no FDA-approved treatments. Its lead candidate JAG201 delivers a functional SHANK3 gene to treat Phelan-McDermid syndrome/genetic autism, while preclinical programs JAG101 (GALT for Type 1 galactosemia) and JAG301 (PAX4 for Type 1 diabetes) extend the pipeline. All programs leverage the company's internal CMC capabilities and commercial-scale GMP manufacturing facility in Durham, NC.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • JAG201 first-in-human trial: Cohort 1 dosing complete with first 3 patients receiving starting dose via ICV injection; first 2 patients in Cohort 2 already dosed. No treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) reported to date. Early indications of clinical benefit observed across neurodevelopmental domains including communicative, motor, cognitive and social.
+2 more records
Product overview1 text field

Jaguar Gene Therapy is advancing a pipeline of AAV9-based gene therapies targeting severe genetic diseases with significant unmet medical need. The core portfolio consists of three investigational programs: JAG201 (lead clinical-stage candidate for SHANK3 haploinsufficiency/Phelan-McDermid syndrome/genetic autism), JAG101 (preclinical for Type 1 galactosemia delivering functional GALT gene), and JAG301 (preclinical for Type 1 diabetes using PAX4-mediated transdifferentiation). Additionally, AXV101 for Bardet-Biedl syndrome is being developed by majority-owned subsidiary Axovia Therapeutics. The company leverages an AAV gene therapy platform with internal CMC capabilities and a 174,000 sq ft commercial manufacturing facility in Durham, NC.

Product and service4 records
1JAG201
CategoryAAV Gene Therapy - CNS / Neurodevelopmental
Description

Investigational AAV9-based gene therapy delivering a functional SHANK3 minigene via intracerebroventricular (ICV) injection to treat SHANK3 haploinsufficiency, a monogenic cause of autism spectrum disorder clinically diagnosed as Phelan-McDermid syndrome. Designed to restore synaptic function required for learning and memory. Currently in Phase I clinical trials for patients with genetic ASD and Phelan-McDermid syndrome.

2JAG101
CategoryAAV Gene Therapy - Metabolic / Rare Disease
Description

Investigational AAV9-based gene therapy delivering a functional GALT gene to address the root cause of Type 1 galactosemia by reducing toxic metabolites (galactose, Gal-1P, galactitol). Currently in preclinical development with encouraging preclinical data showing increased GALT enzyme expression approaching or surpassing wild-type levels in liver and skeletal muscle.

3JAG301
CategoryAAV Gene Therapy - Cell Transdifferentiation / Diabetes
Description

Investigational AAV-based gene therapy using the PAX4 gene to convert alpha cells to beta cells (transdifferentiation) for the treatment of Type 1 diabetes. Currently in preclinical development.

4AXV101
CategoryGene Therapy - Ciliopathy / Rare Disease (via Axovia Therapeutics subsidiary)
Description

Investigational gene therapy treatment for BBS1, a subset of Bardet-Biedl syndrome (BBS). Developed by Axovia Therapeutics, a majority-owned subsidiary of Jaguar Gene Therapy focused on ciliopathies.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

Partnership for late-stage Process Performance Qualification (PPQ) manufacturing of JAG201 gene therapy. Andelyn provides AAV vector manufacturing and GMP production expertise to support JAG201's clinical advancement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-09
Description

Launched Autism Partnership Program in New York collaborating with Jaguar to offer free exome and genome testing to eligible individuals. Program aims to reduce barriers to genetic testing and facilitate earlier diagnosis and targeted treatment development.

Strategic tierCoreTypeOthersAnnounced on2021-10-26
Description

Nation's leading provider of life science real estate. Owns and operates the 174,000-square-foot commercial manufacturing facility in Durham, NC for Jaguar.

Strategic tierFlagshipTypeTechnology or Integration
Description

Exclusive license for JAG201 program targeting SHANK3 haploinsufficiency. Program based on groundbreaking work of Guoping Feng, Ph.D. from Broad Institute. Preclinical proof-of-concept data generated at Broad.

Strategic tierFlagshipTypeTechnology or Integration
Description

Exclusive license for JAG301 program for Type 1 diabetes using PAX4 gene for transdifferentiation. Research agreement in place. Encouraging preclinical proof-of-concept data produced at Tulane.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research agreement in place for JAG101 Type 1 galactosemia program. Encouraging preclinical proof-of-concept data produced in partnership with Emory researchers.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research agreement in place for JAG101 Type 1 galactosemia program. Encouraging preclinical proof-of-concept data produced in partnership with University of Utah researchers.

8Advanced Medicine Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Manufacturing partner for Jaguar's therapeutics. Described as 'soon to be spun out from Jaguar.'

jaguargenetherapy.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage AAV gene therapy platform company developing AAV-based treatments for rare diseases including CNS indications. Direct peer in AAV delivery technology, manufacturing infrastructure, and rare disease strategy.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for rare CNS diseases. Closely comparable to Jaguar in stage, platform (AAV9), therapeutic area (CNS/monogenic), and pipeline depth.

TypeDirect peer
Description

Clinical-stage AAV-delivered gene therapy company focused on rare monogenic CNS diseases, including programs using AAV1 and AAVrh10. Directly comparable target patient population, delivery modality, and pipeline stage to Jaguar's JAG201.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for rare genetic diseases, including CNS and muscular indications. Comparable in modality (AAV), target patient population (rare/monogenic), and development stage.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments primarily for CNS diseases including Parkinson's and Huntington's. Comparable in CNS-targeted AAV platform, pipeline stage, and rare disease focus.

TypeBroad incumbent
Description

Owner of Zolgensma — the first FDA-approved AAV9 gene therapy developed by the same leadership team now at Jaguar. Functions as both a direct platform/technology peer and the source of Jaguar's key personnel and IP heritage.

TypeBroad incumbent
Description

Established commercial-stage genetic medicines company with multiple approved AAV and gene editing therapies for rare neuromuscular diseases. Comparable in gene therapy modality and rare disease focus, but at significantly larger scale and commercialization stage.

TypeBroad incumbent
Description

Commercial-stage rare disease company with approved AAV gene therapy (Roctavian for hemophilia A) and a broader rare disease pipeline. Comparable in gene therapy modality and rare disease commercial strategy, but at substantially larger scale.

TypeBroad incumbent
Description

Commercial-stage rare disease company developing multiple modalities including gene therapy for serious genetic conditions. Comparable in focus on severe genetic/rare diseases, but with a much larger approved-product portfolio.

TypeBroad incumbent
Description

Large pharmaceutical company with an active gene therapy franchise (e.g., beqvez for hemophilia B) and ongoing AAV pipeline. Comparable as a competitor for AAV clinical talent, manufacturing capacity, and rare disease partnerships.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jaguar Gene Therapy

Gene Therapy / Rare Disease Biologicsjaguargenetherapy.com

Jaguar Gene Therapy is a clinical-stage, pre-revenue biotechnology company developing AAV9-based gene therapies — lead candidate JAG201 for SHANK3 haploinsufficiency/Phelan-McDermid syndrome (in first-in-human dosing), plus JAG101 (galactosemia) and JAG301 (Type 1 diabetes) — for patients with severe genetic diseases lacking approved treatments.

What Jaguar Gene Therapy does

Jaguar Gene Therapy is a clinical-stage biotechnology company developing AAV9-based gene therapies for severe genetic diseases with significant unmet medical need. Founded in 2020 by former AveXis leadership and backed by Deerfield Management, the company is headquartered in Lake Forest, Illinois, with process sciences and manufacturing operations in Cary and Durham, North Carolina. Its core product candidates are JAG201, an AAV9 vector delivering a functional SHANK3 minigene via intracerebroventricular (ICV) injection for SHANK3 haploinsufficiency / Phelan-McDermid syndrome (lead clinical-stage program, currently in first-in-human dosing); JAG101, delivering the GALT gene for Type 1 galactosemia (preclinical); and JAG301, using PAX4-mediated transdifferentiation to convert alpha cells into beta cells for Type 1 diabetes (preclinical). A fourth program, AXV101 for BBS1-related Bardet-Biedl syndrome, is being developed by majority-owned subsidiary Axovia Therapeutics.

The company leverages a proven AAV9 delivery platform, exclusive licenses to foundational IP from the Broad Institute (JAG201) and Tulane University (JAG301), and vertically integrated CMC and manufacturing capabilities through a $125 million, 174,000-square-foot commercial facility in Durham, NC, owned by Alexandria Real Estate. JAG201 has received Rare Pediatric Disease, Fast Track, and Orphan Drug designations from the FDA, and Cohort 1 dosing was completed in February 2026 with no treatment-related serious adverse events reported.

Jaguar is pre-revenue and monetizes through eventual commercialization of one-time gene therapy treatments, supplemented by patient identification partnerships (e.g., CureSHANK, Phelan-McDermid Syndrome Foundation, Galactosemia Foundation, NORD) and a diagnostic collaboration with GeneDx. Its go-to-market is anchored in deep engagement with rare-disease patient communities and KOLs at leading academic centers such as Mount Sinai, Rush University, and Boston Children's Hospital, while investor syndicate includes Eli Lilly, Deerfield Management, ARCH Venture Partners, Goldman Sachs, Nolan Capital, Samsung Ventures, and the JDRF T1D Fund.

Jaguar Gene Therapy firmographics

Firmographics
Name
Jaguar Gene Therapy
Legal name
Jaguar Gene Therapy, LLC
Website
https://jaguargenetherapy.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Jaguar Gene Therapy is a clinical-stage, pre-revenue biotechnology company developing AAV9-based gene therapies — lead candidate JAG201 for SHANK3 haploinsufficiency/Phelan-McDermid syndrome (in first-in-human dosing), plus JAG101 (galactosemia) and JAG301 (Type 1 diabetes) — for patients with severe genetic diseases lacking approved treatments.
Ownership category
akta.pro rank

Jaguar Gene Therapy industry classification

Industry
Product category
Gene Therapy / Rare Disease Biologics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV gene therapy
  • Rare disease therapeutics
  • Genetic disease treatment
  • Gene replacement therapy
  • Biologics manufacturing

Where Jaguar Gene Therapy is headquartered

Location

Headquarters

HQ city
Lake Forest
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Jaguar Gene Therapy business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Gene Therapy Development and Commercialization: As a clinical-stage biotechnology company, Jaguar Gene Therapy is pre-revenue. The company is developing investigational gene therapies (JAG101, JAG201, JAG301) targeting severe genetic diseases. Revenue will be generated through commercialization of approved gene therapy products once clinical trials are completed and regulatory approvals are obtained.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Jaguar Gene Therapy product offering

Product offering

Core offering

Jaguar Gene Therapy develops investigational AAV9-based gene therapies targeting the root causes of severe genetic diseases with no FDA-approved treatments. Its lead candidate JAG201 delivers a functional SHANK3 gene to treat Phelan-McDermid syndrome/genetic autism, while preclinical programs JAG101 (GALT for Type 1 galactosemia) and JAG301 (PAX4 for Type 1 diabetes) extend the pipeline. All programs leverage the company's internal CMC capabilities and commercial-scale GMP manufacturing facility in Durham, NC.

Product overview

Jaguar Gene Therapy is advancing a pipeline of AAV9-based gene therapies targeting severe genetic diseases with significant unmet medical need. The core portfolio consists of three investigational programs: JAG201 (lead clinical-stage candidate for SHANK3 haploinsufficiency/Phelan-McDermid syndrome/genetic autism), JAG101 (preclinical for Type 1 galactosemia delivering functional GALT gene), and JAG301 (preclinical for Type 1 diabetes using PAX4-mediated transdifferentiation). Additionally, AXV101 for Bardet-Biedl syndrome is being developed by majority-owned subsidiary Axovia Therapeutics. The company leverages an AAV gene therapy platform with internal CMC capabilities and a 174,000 sq ft commercial manufacturing facility in Durham, NC.

Differentiator

Problem solved

Functional benefit

Products and services

  • JAG201 Investigational AAV9-based gene therapy delivering a functional SHANK3 minigene via intracerebroventricular (ICV) injection to treat SHANK3 haploinsufficiency, a monogenic cause of autism spectrum disorder clinically diagnosed as Phelan-McDermid syndrome. Designed to restore synaptic function required for learning and memory. Currently in Phase I clinical trials for patients with genetic ASD and Phelan-McDermid syndrome.
  • JAG101 Investigational AAV9-based gene therapy delivering a functional GALT gene to address the root cause of Type 1 galactosemia by reducing toxic metabolites (galactose, Gal-1P, galactitol). Currently in preclinical development with encouraging preclinical data showing increased GALT enzyme expression approaching or surpassing wild-type levels in liver and skeletal muscle.
  • JAG301 Investigational AAV-based gene therapy using the PAX4 gene to convert alpha cells to beta cells (transdifferentiation) for the treatment of Type 1 diabetes. Currently in preclinical development.
  • AXV101 Investigational gene therapy treatment for BBS1, a subset of Bardet-Biedl syndrome (BBS). Developed by Axovia Therapeutics, a majority-owned subsidiary of Jaguar Gene Therapy focused on ciliopathies.

Quantifiable outcome

  • JAG201 first-in-human trial: Cohort 1 dosing complete with first 3 patients receiving starting dose via ICV injection; first 2 patients in Cohort 2 already dosed. No treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) reported to date. Early indications of clinical benefit observed across neurodevelopmental domains including communicative, motor, cognitive and social.
  • +2 more outcomes

Companies that use Jaguar Gene Therapy

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles3 records

Jaguar Gene Therapy technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Jaguar Gene Therapy partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and flagship.

  • Andelyn BiosciencescoreStrategic or Co-development Partner · 8 December 2025Partnership for late-stage Process Performance Qualification (PPQ) manufacturing of JAG201 gene therapy. Andelyn provides AAV vector manufacturing and GMP production expertise to support JAG201's clinical advancement.
  • GeneDxcoreStrategic or Co-development Partner · 9 October 2025Launched Autism Partnership Program in New York collaborating with Jaguar to offer free exome and genome testing to eligible individuals. Program aims to reduce barriers to genetic testing and facilitate earlier diagnosis and targeted treatment development.
  • Alexandria Real Estate Equities, Inc.coreOthers · 26 October 2021Nation's leading provider of life science real estate. Owns and operates the 174,000-square-foot commercial manufacturing facility in Durham, NC for Jaguar.
  • Broad Institute of MIT and HarvardflagshipTechnology or IntegrationExclusive license for JAG201 program targeting SHANK3 haploinsufficiency. Program based on groundbreaking work of Guoping Feng, Ph.D. from Broad Institute. Preclinical proof-of-concept data generated at Broad.
  • Tulane UniversityflagshipTechnology or IntegrationExclusive license for JAG301 program for Type 1 diabetes using PAX4 gene for transdifferentiation. Research agreement in place. Encouraging preclinical proof-of-concept data produced at Tulane.
  • Emory UniversitycoreStrategic or Co-development PartnerResearch agreement in place for JAG101 Type 1 galactosemia program. Encouraging preclinical proof-of-concept data produced in partnership with Emory researchers.
  • University of UtahcoreStrategic or Co-development PartnerResearch agreement in place for JAG101 Type 1 galactosemia program. Encouraging preclinical proof-of-concept data produced in partnership with University of Utah researchers.
  • Advanced Medicine PartnerscoreStrategic or Co-development PartnerManufacturing partner for Jaguar's therapeutics. Described as 'soon to be spun out from Jaguar.'

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Jaguar Gene Therapy competitors and assessment

Company assessment

Direct peers

  • Regenxbio: Clinical-stage AAV gene therapy platform company developing AAV-based treatments for rare diseases including CNS indications. Direct peer in AAV delivery technology, manufacturing infrastructure, and rare disease strategy.
  • Taysha Gene Therapies: Clinical-stage gene therapy company developing AAV-based treatments for rare CNS diseases. Closely comparable to Jaguar in stage, platform (AAV9), therapeutic area (CNS/monogenic), and pipeline depth.
  • Passage Bio: Clinical-stage AAV-delivered gene therapy company focused on rare monogenic CNS diseases, including programs using AAV1 and AAVrh10. Directly comparable target patient population, delivery modality, and pipeline stage to Jaguar's JAG201.
  • Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for rare genetic diseases, including CNS and muscular indications. Comparable in modality (AAV), target patient population (rare/monogenic), and development stage.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments primarily for CNS diseases including Parkinson's and Huntington's. Comparable in CNS-targeted AAV platform, pipeline stage, and rare disease focus.

Broad incumbents

  • Novartis (AveXis): Owner of Zolgensma — the first FDA-approved AAV9 gene therapy developed by the same leadership team now at Jaguar. Functions as both a direct platform/technology peer and the source of Jaguar's key personnel and IP heritage.
  • Sarepta Therapeutics: Established commercial-stage genetic medicines company with multiple approved AAV and gene editing therapies for rare neuromuscular diseases. Comparable in gene therapy modality and rare disease focus, but at significantly larger scale and commercialization stage.
  • BioMarin Pharmaceutical: Commercial-stage rare disease company with approved AAV gene therapy (Roctavian for hemophilia A) and a broader rare disease pipeline. Comparable in gene therapy modality and rare disease commercial strategy, but at substantially larger scale.
  • Ultragenyx Pharmaceutical: Commercial-stage rare disease company developing multiple modalities including gene therapy for serious genetic conditions. Comparable in focus on severe genetic/rare diseases, but with a much larger approved-product portfolio.
  • Pfizer (Gene Therapy Unit): Large pharmaceutical company with an active gene therapy franchise (e.g., beqvez for hemophilia B) and ongoing AAV pipeline. Comparable as a competitor for AAV clinical talent, manufacturing capacity, and rare disease partnerships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Jaguar Gene Therapy social profiles

Digital presence

Jaguar Gene Therapy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jaguar Gene Therapy leadership team

Management profile

Number of profiles

Profiles13 records

Jaguar Gene Therapy subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Jaguar Gene Therapy funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jaguar Gene Therapy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jaguar Gene Therapy

What does Jaguar Gene Therapy do?

Jaguar Gene Therapy develops investigational AAV9-based gene therapies targeting the root causes of severe genetic diseases with no FDA-approved treatments. Its lead candidate JAG201 delivers a functional SHANK3 gene to treat Phelan-McDermid syndrome/genetic autism, while preclinical programs JAG101 (GALT for Type 1 galactosemia) and JAG301 (PAX4 for Type 1 diabetes) extend the pipeline. All programs leverage the company's internal CMC capabilities and commercial-scale GMP manufacturing facility in Durham, NC.

Is Jaguar Gene Therapy a public or private company?

Jaguar Gene Therapy is a private company. It is classified as venture growth investor backed and is currently operating.

When was Jaguar Gene Therapy founded?

Jaguar Gene Therapy was founded in 2020. It employs 11 to 50 people.

Where is Jaguar Gene Therapy based?

Jaguar Gene Therapy is headquartered in Lake Forest, United States, in the North America region.

How does Jaguar Gene Therapy make money?

One revenue line is on record: gene Therapy Development and Commercialization.

Who are Jaguar Gene Therapy's main competitors?

Direct peers on record are Regenxbio, Taysha Gene Therapies, Passage Bio, Solid Biosciences and Voyager Therapeutics. Broad incumbents are Novartis (AveXis), Sarepta Therapeutics, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical and Pfizer (Gene Therapy Unit).

Does Jaguar Gene Therapy have an API?

No public API is recorded for Jaguar Gene Therapy.

What industry is Jaguar Gene Therapy in?

Jaguar Gene Therapy's product category is Gene Therapy / Rare Disease Biologics. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireStart Genetic Announces Second Annual Genetic Testing Action Day on July 25, 2026Start Genetic announced the second annual Genetic Testing Action Day, scheduled for July 25, 2026, to raise awareness about the role of genetic testing in helping patients with rare diseases, developmental disabilities, and other conditions obtain diagnoses. A recent Medicaid claims analysis cited in the announcement found that only 16.9% of children with autism receive genetic testing despite longstanding recommendations supporting such evaluation. The campaign is supported by sponsors including Illumina, PYC Therapeutics, Neuren Pharmaceuticals, GRIN Therapeutics, Jaguar Gene Therapy, and MyOme, and operates as an initiative of nonprofit CureSHANK.NewsobserverNC pulls incentives for gene therapy companies to create 400 jobs in DurhamNorth Carolina's Economic Investment Committee cancelled 2021 Job Development Investment Grants (JDIGs) for CARsgen Therapeutics and Jaguar Gene Therapy after both gene therapy companies failed to file mandatory 2024 reports required to maintain the incentives. CARsgen had been eligible for up to $1.6 million in payroll tax rebates for creating 200 jobs and investing $157 million, while Jaguar had been offered more than $2.3 million in potential tax benefits for a $125 million manufacturing plant, though neither company received any state funds before the terminations.PharmiWeb.comJaguar Gene Therapy Announces Successful Completion of Dosing of First Patient Cohort in Clinical Trial Evaluating JAG201 for the Treatment of a Leading Monogenic Cause of Autism Spectrum Disorder KnoJaguar Gene Therapy announced the completion of dosing for Cohort 1 in its first-in-human clinical trial evaluating JAG201 for SHANK3 haploinsufficiency, a monogenic cause of autism spectrum disorder clinically diagnosed as Phelan-McDermid syndrome, with the first three patients receiving the starting dose via intracerebroventricular injection and the first two patients in dose-escalation Cohort 2 already dosed. No treatment-related serious adverse events or dose-limiting toxicities have been reported to date, and early indications of clinical benefit have been observed across communicative, motor, cognitive, and social neurodevelopmental domains. The company anticipates completing target enrollment and dosing in Cohort 2 in Q2 2026 and plans to present initial clinical data in the coming months.PR NewswireAndelyn Biosciences Announces Partnership with Jaguar Gene Therapy to Provide Late-Stage PPQ ManufacturingAndelyn Biosciences has partnered with Jaguar Gene Therapy to perform late-stage Process Performance Qualification (PPQ) manufacturing for JAG201, an investigational gene therapy targeting Phelan-McDermid syndrome. This collaboration leverages Andelyn's AAV vector manufacturing expertise to support the clinical advancement of the therapy developed by Jaguar.BioSpaceAndelyn Biosciences Announces Partnership with Jaguar Gene Therapy to Provide Late-Stage PPQ ManufacturingAndelyn Biosciences, a cell and gene therapy contract development and manufacturing organization based in Columbus, Ohio, has partnered with Jaguar Gene Therapy to perform late-stage Process Performance Qualification (PPQ) manufacturing of JAG201, an investigational gene therapy targeting SHANK3 haploinsufficiency associated with Phelan-McDermid syndrome, a monogenic cause of autism spectrum disorder. Andelyn will leverage its AAV vector manufacturing expertise and GMP production capabilities to support the program. The partnership addresses an unmet medical need, as there are currently no approved medications targeting the underlying cause of Phelan-McDermid syndrome, with existing treatments only managing individual symptoms.JaguargenetherapyJaguar Gene Therapy Announces Samsung and JDRF T1D Fund as New InvestorsJaguar Gene Therapy announced that Samsung Ventures and the JDRF T1D Fund have invested in the company to support its gene therapy development. The funding will be used to expand Chemistry, Manufacturing and Controls (CMC) capabilities and advance IND-enabling activities for preclinical programs targeting Type 1 galactosemia, autism spectrum disorder, and Type 1 diabetes.Business Wire BlogJaguar Gene Therapy Announces Samsung and JDRF T1D Fund as New InvestorsJaguar Gene Therapy announced that Samsung Ventures and the JDRF T1D Fund have invested in the company to support its preclinical pipeline of gene therapies. The funding will be used to expand CMC capabilities and advance IND-enabling activities for programs targeting Type 1 galactosemia, autism spectrum disorder-related disorders, and Type 1 diabetes.BioSpaceJaguar Gene Therapy, UCSF and Others Expand Innovation CapacityJaguar Gene Therapy is building a 174,000-square-foot production plant in Durham, North Carolina, for gene therapies targeting Type 1 diabetes, autism, and galactosemia. The facility, valued at over $125 million, will create over 200 jobs and receive more than $7 million in incentives. UCSF's Weill Neurosciences Building, funded by an $185 million gift, is also opening.Expansion SolutionsJaguar Gene Therapy to Build Manufacturing SiteJaguar Gene Therapy announced plans to invest $125.4 million in a new manufacturing facility in Durham County, North Carolina, creating 200 jobs between 2024 and 2028. The company secured $3.14 million in state funding incentives to support the project, which aims to manufacture clinical and commercial quantities of its AAV-based gene therapies. This expansion reinforces North Carolina's position as a hub for biotechnology and supports Jaguar's pipeline of treatments for conditions such as galactosemia and Type 1 diabetes.